Evidence map›Paper›PMID 29720720›Full record

ArticleThe pharmacogenomics journal2018

Gamma-aminobutyric acid (GABA) receptors genes polymorphisms and risk for restless legs syndrome.

Félix Javier Jiménez-Jiménez, Gara Esguevillas, Hortensia Alonso-Navarro, Martín Zurdo, Laura Turpín-Fenoll, Jorge Millán-Pascual, Teresa Adeva-Bartolomé, Esther Cubo, Francisco Navacerrada, Gemma Amo and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Guideline
  2. International journal of molecular sciences · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. International journal of molecular sciences · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Félix Javier Jiménez-JiménezSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain. fjavier.jimenez@salud.madrid.org.ORCID http://orcid.org/0000-0002-7558-7323
Gara EsguevillasUniversity Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain.
Hortensia Alonso-NavarroSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
Martín ZurdoSection of Neurology, Hospital Virgen del Puerto, Plasencia (Cáceres), Spain.
Laura Turpín-FenollSection of Neurology, Hospital La Mancha-Centro, Alcázar de San Juan (Ciudad Real), Ciudad Real, Spain.
Jorge Millán-PascualSection of Neurology, Hospital La Mancha-Centro, Alcázar de San Juan (Ciudad Real), Ciudad Real, Spain.
Teresa Adeva-BartoloméUnit of Neurology, Hospital Recoletas, Zamora, Spain.
Esther CuboSection of Neurology, Hospital Universitario de Burgos, Burgos, Spain.
Francisco NavacerradaSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
Gemma AmoUniversity Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain.
Ana Rojo-SebastiánDepartment of Medicine-Neurology, Hospital "Príncipe de Asturias", Universidad de Alcalá, Alcalá de Henares (Madrid), Madrid, Spain.
Lluisa RubioDepartment of Medicine-Neurology, Hospital "Príncipe de Asturias", Universidad de Alcalá, Alcalá de Henares (Madrid), Madrid, Spain.
Mónica Díez-FairénFundació per la Recerca Biomèdica i Social Mútua de Terrassa, Terrassa, Barcelona, Spain.
Pau PastorFundació per la Recerca Biomèdica i Social Mútua de Terrassa, Terrassa, Barcelona, Spain.
Marisol CallejaSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
José Francisco Plaza-NietoSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
Belén Pilo-de-la-FuenteSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
Margarita Arroyo-SoleraSection of Neurology, Hospital Universitario del Sureste, Arganda del Rey (Madrid), Madrid, Spain.
Esteban García-AlbeaDepartment of Medicine-Neurology, Hospital "Príncipe de Asturias", Universidad de Alcalá, Alcalá de Henares (Madrid), Madrid, Spain.
José A G AgúndezUniversity Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain.
Elena García-MartínUniversity Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Cáceres, Spain.
Hospital Universitario del Sureste · ESInstituto de Salud Carlos III · ESUniversidad de Alcalá · ESHospital General Universitario de Ciudad Real · ESHospital Recoletas Campo Grande · ESHospital Universitario de Burgos · ESHospital Universitario Príncipe de Asturias · ESHospital Virgen del Puerto · ESMútua Terrassa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The possible role of gammaaminobutyric acid (GABA) in the pathophysiology of restless legs syndrome (RLS) is suggested by the symptomatic improvement achieved with GABAergic drugs. Thalamic GABA levels have shown positive correlation with periodic limb movements indices and with RLS severity. We tried to investigate the possible association between the most common single nucleotide polymorphisms (SNPs) in the GABA receptors (GABR) genes rho1, 2, and 3 (GABRR1, GABRR2, GABRR3), alpha4 (GABRA4), epsilon (GABRE), and theta (GABRQ) with the risk of developing RLS. We studied the genotype and allelic variant frequencies of the most common SNPs in the GABRR1(rs12200969, rs1186902), GABRR2(rs282129), GABRR3(rs832032), GABRA4(rs2229940), GABRE(rs1139916), and GABRQ(rs3810651) genes in 205 RLS patients and 230 age- and gender-matched healthy controls using specific TaqMan assays. The frequencies of the GABRR3 rs832032TT genotype and the allelic variant GABRR3 rs832032T were significantly higher in RLS patients than in controls (odds ratio [95% confidence intervals] 7.08[1.48-46.44] and 1.66[1.16-2.37], respectively), although only the higher frequency of the rs832032T allele remained as significant after multiple comparison analysis, both in the whole series and in the female gender. The frequencies of the other genotypes of allelic variants did not differ significantly between RLS patients and controls. RLS patients carrying the GABRA4 rs2229940TT genotype showed a significantly younger age at onset of RLS symptoms than those with the other two genotypes. These results suggest association between GABRR3rs832032 polymorphism and the risk for RLS, and a modifier effect of GABRA4 rs2229940 on the age of onset of RLS.

Indexed as

Genetic Predisposition to DiseaseAdultAgedAge of OnsetAllelesFemaleGenetic Association StudiesGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideReceptors, GABAReceptors, GABA-ARestless Legs SyndromeRisk FactorsGABRA4 protein, humanGABRR3 protein, humanReceptors, GABAReceptors, GABA-A

Identifiers

PMID29720720
OpenAlexW2802898109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.